GLG Pharma

What GLG Pharma does

GLG Pharma is a privately-held pharmaceutical company headquartered in Jupiter, Florida, founded in 2009, that positions itself around personalized medicine for oncology. According to its stated premise, the company pursues STAT3 inhibition as a therapeutic strategy and employs a proprietary cancer culture platform branded Gx-C3. The intended end users are oncology patients and the clinicians and researchers serving them, though no clinical-stage programs, IND filings, approved products, or named collaborators are documented in the available source material.

The company is led by co-founders Richard Gabriel (CEO and President) and Hector J. Gomez (Chief Medical Officer and Chairman). Reported headcount is in the 1-10 range. The company's public web presence at glgpharma.com is occupied entirely by Booked Scheduler v2.8.5, an open-source conference room reservation system developed by Twinkle Toes Software; the site exposes schedules for "Conference Room 1" and "Conference Room 2" with reservations extending into mid-2026. There is no investor-relations, scientific, pipeline, or product content visible on the domain. Integrations are limited to Google and Facebook OAuth for user authentication.

Commercially, GLG Pharma presents as nascent. No pricing models, customers, revenue figures, partnerships, license agreements, patents, trademarks, awards, regulatory actions, or M&A activity are documented in the source material. The only funding-related data point is a 2012-05-10 record listing the Florida Institute for the Commercialization of Florida Technology as an investor with $0 raised and no lead investor identified. The aggregate signal is of a long-standing but very small oncology platform whose public digital footprint is dominated by an internal scheduling utility, with no documented translation from founding premise to clinical or commercial milestone.

Name

GLG Pharma

Website

https://glgpharma.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

GLG Pharma is a privately held Jupiter, Florida-based oncology company founded in 2009 developing personalized cancer medicine using STAT3 inhibitors and a proprietary cancer culture platform called Gx-C3, with fewer than 10 employees and no documented commercial revenue.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Translational Medicine & Biomarkers (HLAIALAF)

akta.pro secondary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Personalized oncology medicine
• STAT3 inhibitors
• Cancer cell culture
• Precision cancer therapy
• Pharmaceutical research

Headquarters

HQ city

Jupiter

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Core offering

GLG Pharma is a research-stage pharmaceutical company developing personalized medicine approaches for oncology, centered on STAT3 inhibitors and a proprietary novel cancer cell culture platform called Gx-C3. The company's stated focus is using these tools to support individualized cancer therapy research and development. Publicly available operational details on the company's pipeline, products, or commercial activity are not disclosed in the input data.

Product overview

GLG Pharma operates a website powered by Booked Scheduler v2.8.5, an open-source scheduling and reservation platform developed by Twinkle Toes Software. The website provides conference room booking functionality, allowing users to schedule and manage reservations for shared resources including Conference Room 1 and Conference Room 2. The system supports user registration, authentication via Google and Facebook, and provides both schedule view and calendar view interfaces.

Differentiator

Problem solved

Functional benefit

Products and services

• STAT3 Inhibitors Pharmaceutical compounds targeting the STAT3 signaling pathway, developed as the therapeutic core of GLG Pharma's personalized oncology medicine program for cancer indications.
• Gx-C3 Novel Cancer Cell Culture Proprietary novel cancer cell culture system named Gx-C3, positioned to enable personalized medicine research in oncology alongside GLG Pharma's STAT3 inhibitor program.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Recent moves3 records

Expansion highlights2 records

Market position

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/angelvcubed

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GLG Pharma